Paris, France - TISSIUM, a leading medical equipment manufacturing company focused on tissue reconstruction, announced today the successful completion of its Series D funding round, raising a total of $50 million. The round was led by Cathay Health, a prominent healthcare investment firm, with participation from Sofinnova Partners and Crédit Mutuel Innovation. The funding will be used to further advance TISSIUM's innovative technology platform and support the company's ongoing research and development efforts.

TISSIUM, founded in 2013 by Christophe Bancel, was established with the mission to address one of the most persistent challenges in the history of surgical procedures: the reconstruction of damaged tissue and the restoration of its natural function. Building on the groundbreaking discoveries made at the laboratories of Bob Langer and Jeff Karp at MIT, TISSIUM recognized the exceptional potential of its unique polymer-based technology to revolutionize tissue reconstruction across multiple therapeutic areas.

"Our journey at TISSIUM began with the discovery of our first polymer, which opened up new possibilities in tissue reconstruction," said Christophe Bancel, Founder of TISSIUM. "Since then, we have built a comprehensive technology platform that encompasses proprietary polymers, activation technologies, and delivery devices. This funding will enable us to accelerate our research and development efforts, bringing us closer to realizing our vision of transforming the field of tissue reconstruction."